Kanoria Chemicals Boosts Funding With ₹49.5 Cr Promoter Share Allotment

Key Allotment Details

The company's Board of Directors greenlit the issuance of 4,95,000 Non-Convertible, Redeemable Preference Shares (NCRPS).

These shares carry a 7% annual dividend and were priced at a face value of ₹1,000 each.

The total value of this preferential allotment, completed via private placement, totals ₹49.50 crore.

R. V. Investment and Dealers Limited, a promoter group entity, is the allottee.

Strategic Funding Move

This preferential allotment is a strategic step for Kanoria Chemicals to raise essential capital.

By securing funds from a promoter entity, the company reinforces promoter support and strengthens its financial position.

A key advantage of issuing preference shares is that it allows capital infusion without diluting the ownership stakes of existing shareholders, unlike equity fundraising.

Company Background and Financial Context

This allotment follows shareholder approval at an Extra-Ordinary General Meeting (EOGM) on April 1, 2026, to raise the company's authorized share capital from ₹50 crore to ₹100 crore.

The company's Board had previously approved the offer document for these redeemable preference shares on April 13, 2026.

Kanoria Chemicals & Industries Ltd. operates in chemical intermediates and specialty chemicals, with diversified interests.

Financially, the company has faced challenges, including a consolidated net loss in FY25 and a rating downgrade by CARE Ratings in March 2025, citing group exposure as a constraint.

Impact on Shareholders and Operations

Shareholders can expect a company that has secured additional funding, potentially aiding its operational and expansion initiatives.

Existing equity holders' proportional ownership remains unchanged due to the non-dilutive nature of preference shares.

The capital infusion may assist the company in managing its financial obligations and pursuing strategic objectives.

Financial and Operational Risks

Kanoria Chemicals reported consolidated net losses for FY25.

A CARE Ratings downgrade in March 2025 highlighted significant group exposure as a concern.

Past operational issues include a revoked closure order for its Ankleshwar plant in September 2024.

The company also faces risks from potential supply chain disruptions and product dumping.

Recent Financial Performance

The company's standalone revenue increased by 18% to ₹6,783 million in FY25, with EBITDA rising to ₹536 million.

Consolidated revenue from operations saw a 4% increase to ₹15,367 million in FY25.

Investor Focus Areas

Investors will closely monitor how the ₹49.5 crore raised is utilized and its impact on the company's financial performance.

Key focus areas will include the company's ability to overcome past financial challenges and issues related to group exposure.

Future disclosures on operational improvements and profitability trends will be important indicators.